10-Q/A: PetMed Express Restates Financials Due to Accounting Errors, Reports Mixed Results

PetMed Express has filed an amended quarterly report to restate its financials due to errors in sales tax accruals and valuation of deferred tax assets, impacting previously reported results.

Summary

• PetMed Express has restated its financial statements for the three and six months ended September 30, 2023 and 2022, due to accounting errors.
• The errors primarily relate to the incorrect application of U.S. GAAP regarding sales tax liabilities and the valuation of deferred tax assets from the PetCareRx acquisition in April 2023.
• The restatement resulted in a decrease in previously reported net income for both the three and six month periods ended September 30, 2023.
• For the three months ended September 30, 2023, net income was restated to $715,000 from a previously reported loss of $70,000.
• For the six months ended September 30, 2023, net loss was restated to $421,000 from a previously reported loss of $957,000.
• The company also identified material weaknesses in its internal controls over financial reporting as of September 30, 2023.
• Sales for the quarter ended September 30, 2023 were $71 million, an increase of 8.8% compared to the same period last year.
• Sales for the six months ended September 30, 2023 were $149.2 million, an increase of 10.3% compared to the same period last year.
• The company acquired approximately 76,000 new customers in the quarter ended September 30, 2023, compared to 61,000 in the same period last year.
• The company acquired approximately 162,000 new customers in the six months ended September 30, 2023, compared to 130,000 in the same period last year.

Sentiment

Score: 4

Explanation: The document reveals significant accounting errors and internal control weaknesses, which are major negatives. While sales growth and customer acquisition are positive, the need for restatement and control remediation overshadows these gains, resulting in a negative sentiment.

Positives

• The restatement of financials resulted in a positive net income for the three months ended September 30, 2023, compared to a previously reported loss.
• The restatement of financials resulted in a reduced net loss for the six months ended September 30, 2023, compared to a previously reported loss.
• Sales increased by 8.8% for the quarter and 10.3% for the six months ended September 30, 2023.
• The company saw a significant increase in new customer acquisitions for both the quarter and six months ended September 30, 2023.
• The AutoShip program continues to show strong growth, reaching 51% of net sales in the most recent quarter.

Negatives

• The company had to restate its financial statements due to material accounting errors.
• The company identified material weaknesses in its internal controls over financial reporting.
• The company experienced a decrease in working capital primarily due to the PetCareRx acquisition and an increase in inventory.
• Net cash used in operating activities was $0.2 million for the six months ended September 30, 2023, compared to cash provided by operating activities of $5.1 million for the same period last year.
• The company's advertising costs per new customer increased to $73 for the quarter ended September 30, 2023, compared to $64 for the same period last year.

Risks

• The company's operations and financial results are subject to various risks and uncertainties that could adversely affect its business.
• Macroeconomic factors, including inflation and increased interest rates, may impact customer demand and the company's ability to forecast consumer spending patterns.
• Increased competition and price sensitivity among consumers may adversely affect future sales.
• The company's ability to remediate the identified material weaknesses in internal controls is critical for future financial reporting accuracy.
• The company's future interest income may decrease based on several factors, including utilization of cash balances on future investments or partnerships.

Future Outlook

The company expects macroeconomic factors to continue to impact its operations for the remainder of fiscal 2024. The company also expects the current macroeconomic environment and enterprise customer cost optimization efforts to impact its revenue growth rates. The company's future interest income may decrease based on several factors, including utilization of cash balances on future investments or partnerships.

Management Comments

• Management determined that the company incorrectly applied U.S. GAAP as it relates to the sales tax liability.
• Management determined that the company improperly valued the deferred tax asset and goodwill included in its consolidated financial statements.
• Management is taking steps to remediate the material weaknesses in internal controls.
• Management is encouraged by the adoption of the AutoShip program.

Industry Context

The direct-to-consumer pet pharmacy market is competitive, with companies vying for market share through online platforms and advertising. PetMed Express's acquisition of PetCareRx is a strategic move to expand its product offerings and distribution capabilities. The company's focus on customer acquisition and the AutoShip program reflects industry trends towards recurring revenue models and customer loyalty.

Comparison to Industry Standards

• PetMed Express's revenue growth of 8.8% for the quarter and 10.3% for the six months ended September 30, 2023, is moderate compared to some high-growth e-commerce companies in the pet care sector, but is solid for a more established player.
• The company's customer acquisition costs of $73 per new customer for the quarter ended September 30, 2023, are within the range of industry averages, but the increase from $64 in the same period last year indicates a need for more efficient marketing strategies.
• The company's AutoShip program, which now accounts for 51% of net sales, is a positive indicator of customer retention and recurring revenue, aligning with industry best practices.
• The restatement of financials and identification of material weaknesses in internal controls are concerning and highlight the need for improved governance and financial reporting processes, which is a common challenge for companies undergoing rapid growth or acquisitions.
• Compared to competitors like Chewy, which has a larger scale and broader product range, PetMed Express is focusing on a more niche market of pet medications and health products, which may offer a more defensible position in the long term.

Corporate Governance

Stakeholder Impact

• Shareholders are impacted by the restatement of financials and the identification of material weaknesses, which may affect investor confidence.
• Employees may be impacted by changes in internal controls and processes.
• Customers may not be directly impacted by the restatement, but the company's ability to maintain accurate financial reporting is important for long-term stability.
• Creditors may be impacted by the restatement and the company's financial performance.

Next Steps

• The company is developing a remediation plan to improve internal controls over financial reporting.
• The company will continue to test and monitor the new and enhanced controls until management has concluded that they are designed and operating effectively.
• The company will make adjustments to the sales tax liability in future periods as and if it obtains any waivers of interest and penalties or other benefits from its voluntary disclosures and as and if it obtains additional documentation from customers supporting exemption from sales tax.

Key Dates

Keywords

financial restatement, accounting errors, sales tax, deferred tax assets, internal controls, PetCareRx, customer acquisition, AutoShip, net income, sales growth